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Anti-tubulin drugs conjugated to anti-ErbB
antibodies selectively radiosensitize
Stephen R. Adams1, Howard C. Yang2, Elamprakash N. Savariar1, Joe Aguilera2, Jessica L. Crisp1, Karra A. Jones3,
Michael A. Whitney1, Scott M. Lippman4,5, Ezra E.W. Cohen4,5, Roger Y. Tsien1,5,6 & Sunil J. Advani2,5
Tumour resistance to radiotherapy remains a barrier to improving cancer patient outcomes.
To overcome radioresistance, certain drugs have been found to sensitize cells to ionizing
radiation (IR). In theory, more potent radiosensitizing drugs should increase tumour kill and
improve patient outcomes. In practice, clinical utility of potent radiosensitizing drugs is
curtailed by off-target side effects. Here we report potent anti-tubulin drugs conjugated to
anti-ErbB antibodies selectively radiosensitize to tumours based on surface receptor
expression. While two classes of potent anti-tubulins, auristatins and maytansinoids,
indiscriminately radiosensitize tumour cells, conjugating these potent anti-tubulins to anti-
ErbB antibodies restrict their radiosensitizing capacity. Of translational significance, we report
that a clinically used maytansinoid ADC, ado-trastuzumab emtansine (T-DM1), with IR
prolongs tumour control in target expressing HER2þ tumours but not target negative
tumours. In contrast to ErbB signal inhibition, our findings establish an alternative therapeutic
paradigm for ErbB-based radiosensitization using antibodies to restrict radiosensitizer
delivery.
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C
oncurrent chemotherapy and radiotherapy form the basis
of curative organ sparing therapy for patients with locally
advanced cancers1–3. Chemotherapy not only has intrinsic
anti-tumour activity but can sometimes sensitize tumours
to radiation kill. The 1990s saw multiple randomized trials
unequivocally demonstrate combining cytotoxic chemotherapy
(that is, cisplatin, 5-fluorouracil and taxanes) with radiotherapy to
improve tumour control and patient survival4–9. However, the
morbidity of such intensive regimens precludes development of
more potent radiosensitizing chemotherapies10. Shockingly two
decades later, non-targeted cytotoxic chemotherapies continue to
remain the most effective approach for patients treated with
concurrent chemo-radiotherapy.
To be clinically useful, radiosensitizing chemotherapies must
improve the therapeutic index, that is, the level of tumour cell
sensitization must be greater than surrounding normal tissue10–12.
In theory, molecularly targeted radiosensitizers blocking tumour-
specific pathways should increase the therapeutic index of
IR by improving tumour control and decreasing side effects.
Identification of ErbB (EGFR, HER2) playing a role in tumour
radioresistance has led to attempts to sensitize tumours by
inhibiting receptor signalling13–20. However, the efficacy of ErbB
signal inhibition is limited because tumours have parallel signalling
pathways circumventing the blockade21–25. Antibody drug
conjugates (ADC) are emerging as a tumour targeted delivery
strategy to restrict localization of drugs to tumours while sparing
normal tissue26–28. ADC consist of a drug (warhead) covalently
attached to an antibody recognizing a specific cell surface receptor.
ADC binds to cells expressing the receptor, is then internalized by
receptor-mediated endocytosis, and finally the drug is released
from the antibody by the action of endolysosomal proteases.
Maytansinoids and auristatins are potent anti-tubulin drugs that
have been conjugated to antibodies with demonstrated clinical
efficacy29–32. Importantly, we have recently discovered that
monomethyl auristatin E (MMAE) is a radiosensitizer, effective
at the single nM level33.
We hypothesized that therapeutic antibodies to ErbB receptors
could direct delivery of highly potent anti-tubulin drugs in a
receptor-restricted manner to selectively radiosensitize tumours.
To test this hypothesis in tumour model systems, we initially
synthesized two ADC in which the anti-tubulin drug
monomethyl auristatin E was conjugated to cetuximab or
trastuzumab (C-MMAE and T-MMAE, respectively). C-MMAE
and T-MMAE bound and restricted MMAE activity and toxicity
to EGFR and HER2 expressing tumour cells, respectively.
Importantly while free MMAE radiosensitized indiscriminately,
antibody conjugation resulted in targeted MMAE radiosensitiza-
tion to EGFR or HER2 expressing tumours. To delineate the
translational potential of these findings, we extended our studies
to the clinically approved anti-tubulin ADC, ado-trastuzumab
emtansine (T-DM1). We found that T-DM1 radiosensitized
HER2 expressing tumours specifically resulting in significantly
increased tumour xenograft control. On the basis of these
findings, we propose antibody drug conjugate based chemo-
radiotherapy paradigms designed to focus on antibody directed
delivery of highly potent radiosensitizing chemotherapies as an
alternative to receptor signal inhibition.
Results
Efficacy of anti-ErbB antibodies conjugated to Cy5 and MMAE.
To test if ADC can restrict MMAE radiosensitization to
tumours, we conjugated MMAE to cetuximab (C-MMAE) and
trastuzumab (T-MMAE) and labelled them with Cy5 for tracking
(Supplementary Figs 1a and 2). Cetuximab and trastuzumab were
labelled at endogenous cysteines by selective reduction of the four
disulfides in the hinge region and conjugation confirmed by
ES-HPLC, with drug loading measured as B3.7 and B3.2
MMAE per molecule of cetuximab and trastuzumab, respectively
and with B1 Cy5 (refs 34,35). We used thiol-reactive maleimide
derivatives of MMAE containing cathepsin-B cleavable valine–
citrulline linkers that are present in the clinically approved ADC,
brentuximab vedotin. We first evaluated the functionality of
C-MMAE and T-MMAE. EGFR expressing CAL-27 head and
neck cancer (HNC) cells were treated with C-MMAE and imaged
by direct fluorescence (Fig. 1a, Supplementary Fig. 3a). By 30min,
Cy5 fluorescence localized to the cell surface and also was
internalized. We then tested the specificity of C-MMAE and
T-MMAE in a panel of cancer cell lines from different histologies
treated with chemo-radiotherapy, HNC, non-small cell lung
cancer (NSCLC) and esophageal (Fig. 1b, Supplementary Fig. 3a,
Supplementary Table 1). C-MMAE bound to EGFR expressing
CAL-27, A549 and CALU3 cells with decreasing affinity.
T-MMAE demonstrated high affinity to the HER2 expressing cell
lines CALU3, OE19 and BT474. Confocal microscopy results
were validated by measuring cell surface binding of C-MMAE
and T-MMAE (Fig. 1c, Supplementary Fig. 3b). CAL-27 cells
bound to C-MMAE in a dose-dependent manner but not
T-MMAE. In contrast, HER2 expressing cell lines, OE19, CALU3,
and BT474 demonstrated dose-dependent binding of T-MMAE.
We next assessed if C-MMAE and T-MMAE retained MMAE
functional activity of arresting cells in G2/M. Morphologically,
CAL-27 cells treated with either free MMAE or C-MMAE
appeared identical with cells rounding up, indicative of G2/M
(Fig. 1d). OE19 and CAL-27 cells treated with free MMAE
resulted in cells accumulating in G2/M, the most radiosensitive
phase of the cell cycle (Fig. 1e, Supplementary Fig. 4). In OE19
cells, T-MMAE blocked cells in G2/M in contrast to C-MMAE or
antibodies alone which did not influence the cell cycle profile. In
CAL-27 cells, C-MMAE resulted in G2/M arrest. Interestingly,
our Cy5-labelled C-MMAE allowed discrimination of EGFR cell
surface receptor availability that directly correlated with the
potency of C-MMAE to free MMAE in EGFR expressing cell lines
(Supplementary Fig. 5).
Antibody conjugation restricts MMAE radiosensitization. Key
advantages driving the clinical development of MMAE are its
potency and its ability to be tumour targeted through antibody
conjugation27,28. In cell lines we tested, MMAE was more potent
compared with standard cytotoxic chemotherapies that are used
concurrently with radiotherapy in patients, that is, cisplatin and
paclitaxel (Fig. 2a)33. Importantly, C-MMAE or T-MMAE
restricted MMAE cytotoxicity to EGFR or HER2 expressing
cells, respectively, and were much more potent than antibodies
alone (Fig. 2b). Since concurrent chemo-radiotherapy is standard
of care in HNC, NSCLC and esophageal cancers, we tested
whether ADC restricted MMAE radiosensitization in cell lines of
these histologies1–3. Following IR, cells die predominantly as a
result of mitotic catastrophe that can be measured by clonogenic
survival11. CAL-27 cells were treated overnight with MMAE,
cetuximab or C-MMAE and then irradiated. The surviving
fraction following 2Gy decreased in cells treated with free MMAE
or C-MMAE compared with vehicle or cetuximab-treated cells
(Fig. 2c). At these lower drug concentrations, cetuximab had no
radiosensitizing effect. Mechanistically, IR induces cell death by
causing DNA double strand breaks, which can be measured by
neutral comet assay11. Irradiation of vehicle-treated CAL-27 cells
resulted in a 3.6-fold increase in comet tail length that was
significantly increased by 0.5 nM C-MMAE but not by 5 nM
cetuximab (Fig. 2d). Importantly, C-MMAE restricted MMAE
radiosensitization. In low EGFR binding LN229 cells (Fig. 2e,
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Supplementary Fig. 6), irradiation resulted in a 2.5-fold increase
in comet tail length that was not appreciably increased by 20 nM
cetuximab or C-MMAE (Fig. 2d). Interestingly in irradiated
CALU3 cells, 2 nM of free MMAE, C-MMAE or T-MMAE all
resulted in increased comet tail length to a similar degree when
compared with vehicle or 20 nM antibody-treated cells (Fig. 2f).
This result is concordant with cytotoxicity data, which
demonstrated C-MMAE and T-MMAE were equally cytotoxic
in CALU3 cells (Supplementary Fig. 7). In irradiated HER2þ
OE19 cells, 2 nM free MMAE or T-MMAE further increased
comet tail length compared vehicle, 20 nM antibody or 2 nM
C-MMAE treated cells (Fig. 2f).
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Figure 1 | Anti-ErbB antibody MMAE conjugates bind in a receptor-dependent manner. (a) CAL-27 (EGFRþ ) cells exposed to 2 nM of Cy5-labelled
C-MMAE for 30min then incubated in drug-free media. Cells were fixed at indicated times and imaged for Cy5 fluorescence (red). Nuclei stained with
DAPI (blue). Scale bar, 10mm. Representative images of three independent experiments. (b) A panel of EGFR (CAL27, A549, CALU3) and HER2 (CALU3,
OE19, BT474) expressing cells from diverse tumour histologies were exposed to 2 nM Cy5-labelled C-MMAE or T-MMAE for 2 h and Cy5 fluorescence
(red) imaged. Nuclei stained with DAPI (blue). Scale bar, 10 mm. Representative images of three independent experiments. (c) Cell surface binding of
Cy5-labelled C-MMAE or T-MMAE. CAL-27 and OE19 cells incubated on ice with increasing concentrations of C-MMAE or T-MMAE. of Flow cytometry
assessment of Cy5 signal. Representative data of two independent experiments. (d) Phase contrast microscopy of CAL-27 cells treated with 2 nM MMAE,
cetuximab, or C-MMAE overnight. Representative images of three independent experiments. Scale bar, 50mm. (e) Cell cycle profile of OE19 cells treated
with MMAE, ErbB antibodies (cetuximab or trastuzumab) or ADC (C-MMAE or T-MMAE) overnight, stained with propidium iodide and analysed by flow
cytometry. Data representative of two independent experiments.
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Maytansinoids radiosensitize and can be HER2 targeted.
Similar to the auristatins (for example, MMAE), maytansinoids
(for example, mertansine) are another potent class of
anti-tubulins29. Importantly, mertansine forms the warhead of
the trastuzumab ADC T-DM1, and is attached to lysine residues
of trastuzumab through a thiol ether linker (Supplementary
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Figure 2 | Antibody conjugated MMAE selectively radiosensitizes tumour cells. (a) CAL-27 (EGRFþ ) and OE19 (HER2þ ) cells were exposed to a dose
range of cisplatin, paclitaxel or MMAE for 72–96 h. Cell viability normalized to vehicle treated cells and plotted as mean fractional survival±s.d. of three
replicates. Data representative of three independent experiments. (b) CAL-27 and OE19 tumour cells were exposed to dose range of MMAE, ErbB antibody
(cetuximab or trastuzumab) or ADC (C-MMAE or T-MMAE) for 72 h. Cell viability plotted as mean fractional survival±s.d. of three replicates. Data
representative of three independent experiments. (c) Clonogenic cell survival (SF2) of CAL-27 cells treated with MMAE, cetuximab or C-MMAE overnight
followed by 0 or 2Gy. Cell viability normalized to non-irradiated cells for each drug condition and plotted as mean fractional survival±s.d. of six replicates.
Data representative of two independent experiments. (d) CAL-27 and LN229 cells treated with cetuximab or C-MMAE overnight, irradiated with 6Gy, and
comet tail length measured by neutral comet assay. Data normalized to vehicle treated, non-irradiated cells and plotted as mean relative comet tail
length±s.e.m. of 450 cells per group. Data representative of two independent experiments. (e) CAL-27 and LN229 cells exposed to 2 nM Cy5-labelled
C-MMAE for 2 h and Cy5 fluorescence (red) imaged. Nuclei stained with DAPI (blue). Scale bar, 10mm. (f) CALU3 (EGFRþ , HER2þ ) and OE19 cells
treated with free MMAE, ErbB antibodies (cetuximab or trastuzumab) or ADC (C-MMAE or T-MMAE) overnight, irradiated with 6Gy, and comet tail
length measured using neutral comet assay. Comet tail length normalized to vehicle treated, non-irradiated cells and plotted as mean relative comet tail
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Fig. 1b). T-DM1 (Kadcyla) has shown efficacy in HER2
expressing metastatic breast cancer patients29,30. Given our
findings that T-MMAE selectively radiosensitized HER2
expressing cancer cells, we decided to evaluate the more
immediate clinical potential of our strategy by testing if T-DM1
radiosensitized tumours in a HER2þ selective manner. First, we
tested if the maytansinoid warhead of T-DM1 was a bona fide
radiosensitizer. HCT116 or CAL-27 cells were treated overnight
with mertansine and then irradiated with 2Gy. In both cell lines,
the surviving fraction following 2Gy decreased further in cells
treated with free mertansine compared with vehicle (Fig. 3a).
Irrespective of HER2 expression, the IC50 of mertansine was fairly
consistent across cell linesB10 nM (Fig. 3b). In contrast, T-DM1
potency directly correlated with HER2 expression. In HER2þ
cell lines (OE19 and NCI N87 (gastric cancer)) the IC50 of
T-DM1 was o1 nM but was 4100 nM in HER2- cells(HCT116
and CAL-27). From a translation point of view, T-DM1 was a
more potent cytotoxic drug in HER2þ OE19 cells compared
with clinically used radiosensitizers that are either cytotoxic
(paclitaxel and cisplatin) or targeted to HER2 (trastuzumab
and lapatinib) or EGFR (erlotinib) (Fig. 3c). However in
HER2- CAL-27 cells, paclitaxel was more potent than T-DM1
(Supplementary Fig. 8). Functionally, mertansine increased the
accumulation of both OE19 and HCT116 cells in the
radiosensitive G2/M phase of the cell cycle (Fig. 3d). While
T-DM1 also blocked OE19 cells in G2/M, the cell cycle profile
of HCT16 cells treated with T-DM1 resembled vehicle-treated
cells. Next, we tested if T-DM1 would restrict mertansine
mediated radiosensitization in a HER2-dependent manner.
Unconjugated mertansine (20 nM) radiosensitized by increasing
IR induced DNA double-strand breaks in both HER2þ
and HER2 cell lines (Fig. 3e). Importantly, 20 nM T-DM1
resulted in restricted radiosensitization of HER2þ cells.
As with T-DM1’s increased potency and ability to arrest cells in
G2/M confined to HER2þ cells, trastuzumab conjugation
reversed mertansine’s ability to increase IR induced DNA
double-strand breaks, making it appear inert to irradiated
non-HER2 expressing cells. At these dose levels, trastuzumab
did not result in any significant radiosensitization. Moreover,
doses as low as 2 nM T-DM1 radiosensitized OE19 cells
(HER2þ ) as they accumulated in the G2/M phase of the cell
cycle (Fig. 3d,f).
ADC more effectively radiosensitize tumours than free drugs.
We then tested the efficacy of combining ErbB targeted delivery
of anti-tubulins with IR in tumour xenografts. We first focused on
our MMAE synthesized cetuximab and trastuzumab ADC since
Cy5 labelling allows for in vivo ADC visualization, tracking and
serves as a surrogate for tumour drug delivery following intra-
venous injection in mice. Mice bearing OE19 tumours were
intravenously injected with Cy5-labelled C-MMAE or T-MMAE
(Fig. 4a). In these HER2þ tumours, T-MMAE demonstrated
greater Cy5 signal accumulation within tumours compared with
C-MMAE. MMAE target ‘hit’ was validated by staining tumours
for the G2/M marker, pS10 of Histone H3. T-MMAE resulted in
increased pS10 of Histone H3 in tumours while cetuximab con-
jugation blocked MMAE anti-tubulin activity. Sectioned tumour
xenografts demonstrated T-MMAE Cy5 fluorescence localized to
areas of tumour cells and not stroma, an important pre-requisite
for radiosensitizers to improve the therapeutic ratio. T-MMAE
pharmacokinetics, measured by loss of Cy5 fluorescence in the
blood was comparable to that of similar Cy5-labelled antibody
alone (Fig. 4b)36. Conversely in EGFR expressing tumours HNC
(CAL-27, SCC-61, SCC-35 and SQ-9G), NSCLC (A549) and
colorectal (HCT-116), tumour xenografts showed Cy5 signal
accumulation for up to 72 h after C-MMAE injection while
tumours from low EGFR LN-229 did not (Fig. 4c, Supplementary
Fig. 9). Irradiation of tumour xenografts did not appreciably
influence C-MMAE accumulation in tumours. EGFRþ tumour
xenografts from mice treated with C-MMAE showed increased
accumulation in G2/M by pS10 Histone H3 staining compared
with cetuximab, verifying delivery of active MMAE to tumours
(Fig. 4d). Importantly, tumour MMAE concentrations from
CAL-27 xenografts injected with C-MMAE or T-MMAE
confirmed restriction of released drug to EGFRþ cells by
cetuximab conjugation as opposed to trastuzumab conjugation
(Fig. 4e). Next, we assessed the efficacy of anti-ErbB antibody
MMAE conjugates in combination with IR on tumour regression.
Mice with CAL-27 tumours were treated with vehicle, free
MMAE, cetuximab or C-MMAE on day 0 (Fig. 4f). Cetuximab
and C-MMAE were injected at a dose of 0.5 nmol (B3.6 and
B4mg kg 1, respectively). Since an average of four molecules of
MMAE were conjugated to each antibody molecule, a dose of
2 nmol of free MMAE was injected to maintain MMAE dose
equivalence to C-MMAE. Because C-MMAE persisted in murine
xenografts for up to 72 h (Fig. 4c), 3 Gy was given on days 1
and 2. In non-irradiated tumours, both free MMAE and
cetuximab alone delayed tumour growth, which was further
slowed by C-MMAE. Importantly, delivering IR with C-MMAE
significantly increased tumour growth delay, Po0.0001
compared with all other experimental groups by day 35 post
initiation of treatment (Supplementary Table 2). To specifically
ascertain the advantage of using ADC in combination with IR, we
tested C-MMAE compared with co-administered free MMAE
and cetuximab (Fig. 4g). Interestingly in irradiated groups, mice
receiving C-MMAE had significantly smaller tumours than those
receiving co-administered cetuximab and free MMAE, Po0.05
by day 28 (Supplementary Table 3). In both experiments, mice
tolerated therapies well as measured by weekly weights
(Supplementary Fig. 10). These results reveal the advantages of
using antibody conjugated MMAE as a radiosensitizer as opposed
to the combination of antibodies with cytotoxic drugs on tumour
control and is line with recent negative results from phase III
clinical trials37,38.
T-DM1 and IR prolong HER2þ but not HER2 tumour control.
Given these findings with C-MMAE and T-MMAE in EGFRþ
and HER2þ tumour xenografts, we next evaluated T-DM1 since
it is already clinically approved and its safety established in
women with metastatic breast cancer30. First, we compared the
potency of auristatins and maytansinoids conjugated to
trastuzumab. In HER2þ OE19 and CALU3 cells, T-MMAE
and T-DM1 had similar potency (Fig. 5a, Supplementary Fig. 11).
In OE19 HER2þ tumour xenografts, a single dose of 1 nmol
of either T-MMAE or T-DM1 (B7.7 and B7.4mg kg 1,
respectively) were equally efficacious in slowing tumour growth
compared with control or trastuzumab by day 14 (Fig. 5b,
Supplementary Table 4). While T-DM1 increased apoptosis, it
also increased the number of cells in radiosensitive G2/M phase of
the cell cycle, as measured by pS10 Histone H3 (Fig. 5c). Given
the equivalence of T-MMAE and T-DM1 in cell culture and
tumour xenografts, we then focused on optimizing dosing of
T-DM1 and IR to determine if combining the two treatments
would produce long term tumour control specifically in HER2þ
tumour xenografts. We dose reduced T-DM1 to 0.25 nmol
(B1.9mg kg 1) delivered once (day 0). On the basis of our
above results with our Cy5-labelled ADC, ADC localized within
tumours for up to 72 h. Therefore, we delivered 2.5 Gy of IR on
days 1, 2 and 3 after T-DM1 injection. In both OE19 and NCI
N87 HER2þ tumour xenografts, this regimen resulted in
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significantly prolonged tumour regression (Fig. 5d), increased
doubling time (Table 1, Supplementary Table 5),
while mice maintained their weight (Supplementary Fig. 10).
By day 22 in OE19 and day 32 in NCI N87 tumour xenografts,
T-DM1 combined with IR was superior to all other treatment
regimens (Supplementary Tables 6 and 7). In stark contrast,
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cells per group. Scale bar, 50mm. All statistical significances were calculated using one-way ANOVA with Tukey’s multiple comparisons test. *Po0.05,
**Po0.01, ****Po0.0001.
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HER2- HCT116 tumour xenografts showed no benefit of adding
T-DM1 to IR (Fig. 5d, Table 1, Supplementary Table 8). Of
potential clinical value, long term tumour control was observed
when T-DM1 was combined with IR in HER2þ tumours
(Fig. 5e, Supplementary Table 9).
Discussion
Unresectable, locally advanced cancers continue to pose a
therapeutic challenge1–3. The most effective chemo-
radiotherapy strategies to date integrate non-targeted cytotoxic
chemotherapies3–9,39,40. However, such therapeutic intensification
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increases normal tissue toxicities often precluding further
radiotherapy or chemotherapy dose escalation10. To mitigate
treatment related side effects and allow for more potent
radiosensitizing chemotherapies, tumour targeted radio-
sensitization approaches are required. While targeted drug
therapies have advanced for certain cancer patients with
specific mutations, outside of cetuximab none have
demonstrated unequivocal clinical utility with radiotherapy
when compared directly with non-targeted cytotoxic
chemotherapies12,13,41,42. Frustratingly, adding cetuximab to
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cytotoxic chemo-radiotherapy in NSCLC or HNC patients failed to
improve outcomes37,38.
While inhibiting ErbB signalling is an appealing approach to
radiosensitize tumours, attempted blockage of receptor tyrosine
kinase signalling results in activation of bypass pathways, that is
the ‘whack a mole’ problem21,24,25. To overcome this, we propose
an alternative ErbB mediated radiosensitization paradigm based
on ErbB directed ADC that is more potent and potentially
superior to signal inhibition. We initially evaluated the auristatin
class (MMAE) of anti-tubulins as ADC-based radiosensitizers for
three reasons. First, it is the ‘warhead’ of brentuximab vedotin,
a clinically used ADC for CD30 lymphomas that is attached
through a cathepsin B sensitive and self-immolative linker.
Moreover, this allowed for direct measurement of tumour drug
delivery (Fig. 4)35. Second, we have previously demonstrated that
in addition to its cytotoxic activity, MMAE is a potent
radiosensitizer33. Finally, Cy5 labelling during ADC synthesis
allowed for non-invasive imaging of ADC localization and served
as a marker for antibody targeting which was validated by tumour
drug delivery and activity of blocking cells in G2/M. Our
synthesized ADC showed tumour accumulation of T-MMAE or
C-MMAE in a receptor-restricted manner which resulted in
tumour selective MMAE radiosensitization. Given our findings
with C-MMAE and T-MMAE, we extended our studies to the
clinically approved ADC, T-DM1. As with auristatins, we found
that the maytansinoid class of anti-tubulins also were potent
radiosensitizers as either free drug or as the trastuzumab ADC,
T-DM1 (Figs 3 and 5).
Delivering ADC with IR has several advantages that can result
in improved patient outcomes: (1) Combinatorial therapy attacks
cancer cells by multiple mechanisms decreasing the risk of
tumour resistance emerging. (2) Instead of higher individual
doses of a single agent to achieve effective tumour kill,
combinatorial therapy allows for dose reduction of each
individual modality thereby decreasing the toxicities inherently
associated with each therapy. (3) concurrent delivery of full dose
chemotherapy and radiotherapy allow for attacking not only
known local disease but also potential micrometastases.
(4) Ideally, chemotherapies used in conjunction with radio-
therapy will be highly potent alone, synergize with IR, and be
spatially targeted to tumours and not normal tissue. (5) The
precise timing with which IR can be delivered is valuable for
defining the temporal window(s) when radiosensitization should
be maximal. Auristatin and maytansinoid based ADC fulfill these
criteria. Currently, there are only two indications for which ADC
has shown clinical value, CD30 lymphomas and HER2 metastatic
breast cancer30,31. Our studies and in particular those involving
T-DM1, suggest integrating ADC in the curative setting for
locally advanced solid tumours. HER2 overexpression occurs in a
proportion of lung, esophageal, gastric and bladder cancers,
which are treated with concurrent chemo-radiotherapy2,3,43,44.
On the basis of our findings, T-DM1 provides potent and
tumour selective radiosensitization that warrants speedy clinical
evaluation and may help expedite the evolution of tumour
radiosensitization from decades old non-targeted cytotoxins to a
biomarker-driven tumour-targeted paradigm.
Methods
Cells and reagents. All cell lines used in these studies are summarized in
Supplementary Table 1. Human HNC (CAL-27, SCC-25), NSCLC (A549, CALU3),
colorectal (HCT-116), gastric (NCI N87), glioma (LN229) and breast (BT474)
cancer cell lines were obtained from American Type Culture Collection. Human
esophageal cancer line OE19 was obtained from Sigma-Aldrich. Human HNC
SCC-35, SCC61 and SQ-9G was kindly provided from Ralph Weichselbaum,
University of Chicago. CAL-27, A549 and HCT116, cells were cultured in DMEM
supplemented with 10% FBS. SCC-61 was cultured in DMEM/F12 supplemented
with 20% FBS and 400 ngml 1 hydrocortisone. OE19 and NCI N87 cells were
cultured in RPMI supplemented with 10% FBS. CALU3 cells were cultured in
MEM supplemented with 10% FBS. On receipt, each cell line was expanded,
cryopreserved as low passage stocks and routinely tested for mycoplasma. Cisplatin
(Enzo Biosciences), paclitaxel (Sigma), MMAE (Concortis) and mertansine
(Abcam) were reconstituted in DMSO. Clinical-grade erlotinib, lapatinib,
cetuximab, trastuzumab, ado-trastuzumab emtansine (T-DM1) were obtained from
UCSD Moores Cancer Center pharmacy.
Synthesis of MMAE and Cy5 anti-ErbB antibodies conjugates. A solution
(1ml, 2mgml 1) of cetuximab (Erbitux, ImClone) or trastuzumab (Herceptin,
Roche) was treated with sodium bicine buffer (100 ml, 1M pH 8.3) and sodium
diethylenetriaminepentaacetic acid (10 ml, 100mM pH 7). Following reduction
with four equivalents of tris(carboxyethyl)phosphine (TCEP) at 37 C for 2 h, the
solution was added to four equivalents of maleimidocaproyl-valine-citrulline-
PABA-MMAE (MC-VC-MMAE)33. After 30min at room temperature, Cy5-
maleimide (2 equivalents) was added and after a further 30min, gel-filtered
(Sephadex G25, 0.6 g) eluting with PBS. Following centrifugal concentration
(Centricon 30 kDa MWCO) to 500 ml, the concentrations of antibody and Cy5 were
determined by absorbance using extinction coefficients of 210,000M 1 cm 1
(cetuximab) or 225,000M 1 cm 1 (trastuzumab) at 280 nm and
12,500M 1 cm 1 and 250,000M 1 cm 1 at 280 and 650 nm, respectively, for
Cy5. Hydrophobic interaction chromatography (HIC) of a reaction sample after
labelling with MMAE revealed nine peaks corresponding to antibody modified
with 0–8 MMAE derivatives if up to four disulfides are reduced by TCEP per
antibody34 (Supplementary Fig. 2a,c). Subsequent Cy5-maleimide labelling gave
650 nm absorbance to each peak apart from that labelled with eight MMAE as no
cysteines are available for further conjugation (Supplementary Fig. 2b,d). Drug
loading was measured by denaturing reverse-phase HPLC of the reaction mix
before addition of Cy5 maleimide, following reduction of any remaining
intersubunit disulfides with 50mM DTT for 30min (ref. 45). Peaks corresponding
to light or heavy chains46,47 with 0–3 MMAE were identified by electro-spray mass
spectroscopy (Supplementary Fig. 2e–h) and peak areas at 280 nm were integrated
and weighted to calculate the drug loading26. Modified light chain (L1) and
unmodified H chain (H0) were not resolved for trastuzumab so MMAE loading is
an underestimate. No free MC-VC-MMAE was detected by HPLC following gel
filtration. This conjugation chemistry that we utilized has subsequently been shown
to undergo a slow retro-Michael reaction resulting in loss of the MMAE-linker
from the antibody in the circulation and potential off-target toxicity. Modifications
have been devised to decrease premature release of the warhead but have yet to be
clinically approved, so we retained the established linker48.
Cy5 fluorescence imaging. Cells were exposed to Cy5-labelled cetuximab-MMAE
or trastuzumab-MMAE for 30min in media with 1% serum. Cells were then
washed with PBS and incubated in media with 10% serum. At indicated times, cells
were fixed in 4% paraformaldehyde and then stained with DAPI. Cells were imaged
using a Nikon A1R confocal microscope.
ADC cell binding. Cells were collected and resuspended in cold PBS with 5% BSA.
Cy5-labelled cetuximab-MMAE or trastuzumab-MMAE was added to the cells at
indicated concentrations for 15min on ice. Cells were washed, resuspended in PBS
with 5% BSA and 0.5 mgml 1 propidium iodide, and analysed by flow cytometry.
Cell cycle. Cells were treated with MMAE, mertansine, cetuximab or cetuximab-
MMAE, trastuzumab, trastuzumab-MMAE or T-DM1 for 24 h and then fixed in
methanol. Cells were treated with RNAse, stained with propidium iodide (PI) and
analysed by FACS using FloJo software.
Alamar blue assay. Cells were plated in 96-well plates and exposed to a range
of concentrations of MMAE, mertansine, cisplatin or paclitaxel, cetuximab,
cetuximab-MMAE, trastuzumab-MAME or T-DM1 for 72 h. Alamar Blue
(resazurin) was added to the cells and allowed to incubate for 2–4 h at 37 C.
Plates were analysed using a plate reader with fluorescence measured at 560 nm.
Table 1 | T-DM1 combined with IR increases HER2+ tumor
control.
OE19 NCI N87 HCT116
Control 7 (5–14) 9 (7–16) 3 (2–5)
Trastuz 6 (4–8) 14 (10–21) 4 (2–8)
T-DM1 11 (8–17) 23 (21–25) 3 (2–5)
IR 9 (7–11) 14 (11–20) 6 (4–9)
Trastuzþ IR 14 (10–24) 19 (16–22) 7 (5–12)
T-DM1þ IR 66 (33þ ) 113 (82–179) 7 (5–12)
Tumour doubling time in days (mean, 95% CI) of mice in Fig. 4d bearing OE19 or NCI N87
(HER2þ ) or HCT116 (HER2 ) tumour xenografts.
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Clonogenic assay. Cells were treated with MMAE, mertansine, cetuximab or
cetuximab-MMAE for 24 h and then irradiated with 2Gy. Following IR, cells were
counted, re-plated at varying cell numbers in drug-free media. 10–14 days after
initial seeding formed colonies were methanol fixed, stained with crystal violet and
counted. Surviving fraction at 2Gy (SF2) was calculated as the fraction of cells
surviving 2Gy compared with non-irradiated cells.
Neutral comet assay. Cells were treated with indicated times doses of MMAE,
mertansine, cetuximab, cetuximab-MMAE, trastuzumab, trastuzumab-MMAE or
T-DM1 overnight, and then irradiated with 6Gy. Cells were collected 15min post
IR, suspended in agarose gel and lysed per assay directions (Trevigen). Samples
underwent electrophoresis under neutral conditions and were then stained with
Sybr Green. Comet tails were counted in multiple fields (460 cells per sample) and
analysed using CometScore (TriTek Corp). Comet tail length was normalized to
vehicle-treated, non-irradiated cells.
Immunoblotting. Cells were collected and lysed in RIPA buffer (20mM Tris pH 8,
150mM NaCl, 5mM EDTA, 1% Triton X-100) with protease and phosphatase
inhibitors (Complete Protease Inhibitor Cocktail and Phos-Stop, Roche). Lysate
protein was quantitated by BCA technique (Pierce). Twenty micrograms of lysate
underwent electrophoresis using 4–12% Bis-Tris gels (Life Technologies),
transferred to PVDF membranes (iBlot) and incubated with indicated primary
antibodies HER2, GAPDH (Cell Signaling Technology, catalogue numbers 2242
and 2118) and EGFR (Millapore, catalogue number 06-847) at dilutions of 1:1,000,
1:3,000 and 1:3,000, respectively. Blots were developed by ECL (Pierce). Uncropped
blots are shown in relevant Supplementary Figures.
Immunohistochemistry. Tissue sections were cut from blocks of formalin-fixed
paraffin embedded xenografts. Four micron thick tissue sections were stained with
antibodies to phospho-histone H3 (pH3, Abcam, catalogue number ab32107) and
cleaved caspase-3 (ClC3, Cell Signaling Technology, catalogue number 9661) and
used at dilutions of 1:300 and 1:900, respectively. Slides were stained on a Ventana
Discovery Ultra (Ventana Medical Systems, Tucson, AZ, USA). Antigen retrieval
was performed using CC1 for 24–40min at 95 C. The primary antibodies were
incubated on the sections for 1 h at 37 C. Primary antibodies were visualized used
DAB as a chromagen using the UltraMap system (Ventana Medical systems)
followed by hematoxylin as a counterstain. Slides were rinsed, dehydrated through
alcohol and xylene and coverslipped.
Whole slide scanning and immunostaining quantitation. Immunostained slides
were scanned using an Axio Scan.Z1 (Zeiss; Oberkochen, Germany). Axio Scan
uses the software Zen2 (Zeiss) for automatic thresholding and tissue detection.
The entire tissue section encompassing the xenograft was scanned at 40
(0.95 numerical aperture) using the default stitching parameters to combine the
individual tiles into a single image. Whole-slide images were imported into
Definiens Software for quantitative analysis (Definiens; Munich, Germany). Using
Definiens Tissue, tumour regions of interest (ROI) were chosen per slide based on
the pH3 immunostain. The software uses the color contrast of the DAB and
hematoxylin counterstain to determine the basic ROI. Training was done to
exclude non-tumour tissue including necrotic regions and mouse stroma. The ROI
defined for the pH3 stain was also used to analyse the adjacent section stained for
ClC3. For analysis of pH3 (a nuclear stain), the total number of nuclei and the total
number of nuclei showing DAB staining (pH3 positive cells) were recorded within
each ROI. The percent of positive nuclei was then calculated for each sample. For
analysis of ClC3 (a cytoplasmic stain), mean DAB chromagen intensity was
measured and calculated within the ROI for each sample.
In vivo tumour xenograft optical imaging. All animal work was done in com-
pliance with the University of California San Diego Institutional Animal Use and
Care Committee. Six-to-eight-week-old female athymic nu/nu mice purchased
from the University of California San Diego Animal Care Program breeding colony
were injected subcutaneously into the bilateral upper thighs with 5 106 CAL-27,
SQ9-G, SCC-35, SCC-61, A549, HCT-116, OE19 or LN229 tumour cells in a 1:1
Matrigel (BD) and PBS solution. After tumours grew to 4100mm3 they were
injected with 0.5 nmol of Cy-labelled cetuximab-MMAE, trastuzumab-MMAE
(B4 andB3.9mg kg 1, respectively) as described above. For imaging, mice were
anaesthetized (1:1 mixture of 100mgml 1 of ketamine and 5mgml 1 of
midazolam). Animals were imaged using a Maestro Small Animal Imager (CRI)
with excitation filter of 620/22 and 645 nm long-pass emission filter with dichroic
filter tuned to 670 nm. Imaging was done both with skin on and after skin removal
to decrease autofluorescence and scattering. For blood clearance studies, athymic
nu/nu mice were anaesthetized with isoflurane and dosed with 5 nmol of the
antibody conjugates (B36.4 trastuzumab and B38.6mg kg 1 T-MMAE).
At various time points after injection, the tail was pricked and a small volume
(5–10 ml) of blood was collected in a heparinized hematocrit tube. Fluorescent
images were taken using the Maestro, with the filters mentioned above, and the
integrated fluorescent intensity was measured using Image J.
In vivo tumour xenograft experiments. CAL-27, OE19, NCI N87 and HCT116
tumour xenografts were established and tumour growth was measured with digital
calipers. Tumour volume was measured blindly to treatment group and calculated
using the formula as ½ lengthwidth2. Mice were randomized into groups once
the average tumour volume reached 4100mm3. Mice were assigned to indicated
groups in ‘Results’. MMAE, cetuximab, trastuzumab, C-MMAE, T-MMAE or
T-DM1 was intravenously injected in 50 ml. For irradiated mice, the tumour-
bearing hindlimbs were focally irradiated while the remainder of the mouse was
shielded from IR with custom designed lead blocking495% of the dose as verified
by dosimeters placed on the mouse. Free MMAE was injected on an equimolar
basis to C-MMAE in final volume of 3% DMSO. Drug doses and IR fractionation
are as indicated in ‘Results’. To prevent unnecessary morbidity, mice were killed if
tumour length exceeded 15mm per protocol. Nonlinear regression least squares fit
was used to calculate tumour volume doubling times. Tumour doubling times were
extrapolated for T-DM1þ IR groups where tumour doubling was been achieved.
To minimize the number of mice used, tumours were grown in the bilateral flanks.
For CAL-27 tumour xenografts in experiment Fig. 4f, the number of mice and
tumours per group were: control (5 mice, 10 tumours), IR (5 mice, 10 tumours),
MMAE (4 mice, 8 tumours) MMAEþ IR (5 mice, 10 tumours), cetuximab (5 mice,
10 tumours), cetuximabþ IR (5 mice, 10 tumours), C-MMAE (4 mice, 8 tumours),
C-MMAEþ IR (5 mice, 10 tumours). For CAL-27 tumour xenografts in
experiment Fig. 4g, the number of mice and tumours per group were: control
(4 mice, 8 tumours), IR (5 mice, 10 tumours), cetuximabþMMAE (5 mice,
10 tumours) cetuximabþMMAEþ IR (5 mice, 10 tumours), C-MMAE (5 mice,
10 tumours), C-MMAEþ IR (5 mice, 10 tumours). For OE19 tumour xenografts in
experiment Fig. 5b, the number of mice and tumours per group were: control
(5 mice, 10 tumours), trastuzumab (5 mice, 10 tumours) T-MMAE (5 mice,
10 tumours), T-DM1 (5 mice, 10 tumours). For OE19 tumour xenografts in
experiment Fig. 5d,e and Table 1, the number of mice and tumours per group were:
control (5 mice, 10 tumours), IR (5 mice, 10 tumours), trastuzumab (5 mice,
10 tumours), trastuzumabþ IR (5 mice, 10 tumours), T-DM1 (5 mice, 10 tumours)
and T-DM1þ IR (5 mice, 10 tumours). For NCI N87 tumour xenografts in
experiment Fig. 5d,e and Table 1, the number of mice and tumours per group were:
control (2 mice, 4 tumours), IR (3 mice, 6 tumours), trastuzumab (3 mice,
6 tumours), trastuzumabþ IR (4 mice, 8 tumours), T-DM1 3 mice, 6 tumours) and
T-DM1þ IR (4 mice, 8 tumours). For HCT116 tumour xenografts in experiment
Fig. 5d,e and Table 1, the number of mice and tumours per group were: control
(3 mice, 6 tumours), IR (4 mice, 8 tumours), trastuzumab (3 mice, 6 tumours),
trastuzumabþ IR (3 mice, 6 tumours), T-DM1 (3 mice, 6 tumours) and T-DM1þ
IR (4 mice, 8 tumours).
Tumour xenograft drug measurement. Tumours were excised, weighed and
homogenized in 10 volumes of PBS with a point sonicator (Fisher Scientific) using
an amplitude range of 5–15% for a maximum of 20 s while on ice. The homo-
genates were centrifuged (14g, 10min), then the supernatants were collected and
diluted two-fold by addition of 2% acetic acid in acetonitrile, then centrifuged again
(14g, 10min). MMAE concentration was determined by LC-MS/MS with Luna-2
C18 column and Agilent Trap XCT mass spectrometer and extracted fragment ion
currents at 686.4 and 506.4 were integrated and combined to improve sensitivity.
Statistical analysis. Unpaired two-sided t-tests were performed for IC50 and
radiosensitization experiments in cell culture. In tumour regression studies,
two-way ANOVA analysis was performed with Tukey’s multiple comparison
group. Survival curves were analysed log-rank. Tumour doubling volume times
were analysed by determining 95% confidence intervals. All statistical analyses were
performed using Prism software (GraphPad). Statistical analysis for all tumour
xenograft data are presented in Supplementary Tables 2–9.
Data availability. All relevant data are available from the authors.
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